EP3973586A4 - Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs - Google Patents

Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs Download PDF

Info

Publication number
EP3973586A4
EP3973586A4 EP19929933.0A EP19929933A EP3973586A4 EP 3973586 A4 EP3973586 A4 EP 3973586A4 EP 19929933 A EP19929933 A EP 19929933A EP 3973586 A4 EP3973586 A4 EP 3973586A4
Authority
EP
European Patent Office
Prior art keywords
behavioral
methods
pharmaceutical compositions
cognitive disorders
novel pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19929933.0A
Other languages
German (de)
English (en)
Other versions
EP3973586A1 (fr
Inventor
Jianmin Wang
Geping Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Pharma Tech Inc
Original Assignee
La Pharma Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Pharma Tech Inc filed Critical La Pharma Tech Inc
Publication of EP3973586A1 publication Critical patent/EP3973586A1/fr
Publication of EP3973586A4 publication Critical patent/EP3973586A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
    • Y02P70/50—Manufacturing or production processes characterised by the final manufactured product

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19929933.0A 2019-05-21 2019-05-21 Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs Pending EP3973586A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/033359 WO2020236159A1 (fr) 2019-05-21 2019-05-21 Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs

Publications (2)

Publication Number Publication Date
EP3973586A1 EP3973586A1 (fr) 2022-03-30
EP3973586A4 true EP3973586A4 (fr) 2023-01-11

Family

ID=73459142

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19929933.0A Pending EP3973586A4 (fr) 2019-05-21 2019-05-21 Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs

Country Status (6)

Country Link
EP (1) EP3973586A4 (fr)
JP (1) JP2022539944A (fr)
CN (1) CN114072945A (fr)
AU (1) AU2019446955A1 (fr)
CA (1) CA3139082A1 (fr)
WO (1) WO2020236159A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10966989B2 (en) 2019-04-12 2021-04-06 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11389458B2 (en) 2019-04-12 2022-07-19 LA PharmaTech Inc. Pharmaceutical compositions and methods for treating parkinson's and huntington's disease
US11318144B2 (en) 2019-04-12 2022-05-03 LA PharmaTech Inc. Compositions and methods for treating Alzheimer's disease and Parkinson's disease
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US10639314B1 (en) 2019-04-30 2020-05-05 LA PharmaTech Inc. Method of treating Alzheimer's disease
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11351179B1 (en) 2021-08-05 2022-06-07 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of psychiatric disorders
WO2024072049A1 (fr) * 2022-09-26 2024-04-04 주식회사 지투지바이오 Association pharmaceutique contenant du donépézil et de la rivastigmine pour prévenir, soulager ou traiter la démence ou la déficience cognitive et procédé de préparation s'y rapportant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152108A1 (en) * 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1298715C (zh) * 2001-03-13 2007-02-07 先灵公司 作为组胺h3拮抗剂的非咪唑化合物
KR20040022238A (ko) * 2001-08-09 2004-03-11 오노 야꾸힝 고교 가부시키가이샤 카르복실산 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
WO2015032966A1 (fr) * 2013-09-09 2015-03-12 Sanofi Antagoniste des récepteurs h3 combiné à un inhibiteur de la cholinestérase et utilisé dans le cadre du traitement de la maladie d'alzheimer
US20210322447A1 (en) * 2020-04-16 2021-10-21 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of psychedelics derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152108A1 (en) * 2006-10-27 2010-06-17 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AIKO HATAKEYAMA ET AL: "AZELASTINE HYDROCHLORIDE ON BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS AND ACTIVITIES OF DAILY LIVING IN DEMENTIA PATIENTS", GERIATR. GERONTOL. INT,, vol. 8, 1 January 2008 (2008-01-01), pages 59 - 61, XP002798078 *
ANONYMOUS: "Donepezil -Medline Plus", MEDLINE PLUS, 15 December 2017 (2017-12-15), pages 1 - 7, XP093003741, Retrieved from the Internet <URL:https://medlineplus.gov/druginfo/meds/a697032.html> [retrieved on 20221130] *
ANONYMOUS: "EPAR summary for the public", EUROPEAN MEDICINES AGENCY, 1 December 2012 (2012-12-01), pages 1 - 3, XP093003735, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/overview/prometax-epar-summary-public_en.pdf> [retrieved on 20221130] *
ANONYMOUS: "RAZADYNE-galantamine hydrobromide tablet, film coated Rebel Dis tributors Corp", DAILYMED, 11 November 2010 (2010-11-11), pages 1 - 29, XP093003743, Retrieved from the Internet <URL:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e62efb5a-d2cc-4e11-9e61-10e65ef3d897> [retrieved on 20221130] *
See also references of WO2020236159A1 *

Also Published As

Publication number Publication date
JP2022539944A (ja) 2022-09-14
WO2020236159A1 (fr) 2020-11-26
CA3139082A1 (fr) 2020-11-26
EP3973586A1 (fr) 2022-03-30
CN114072945A (zh) 2022-02-18
AU2019446955A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
EP3952840A4 (fr) Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
EP3973586A4 (fr) Nouvelles compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
EP3351616A4 (fr) Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive
EP3934652A4 (fr) Composés, compositions et procédés pour le traitement d&#39;une maladie
EP3931189A4 (fr) Azépino-indoles et autres hétérocycles pour traiter des troubles du cerveau
EP3999085A4 (fr) Méthodes et produits destinés au traitement de troubles gastro-intestinaux
EP3962488A4 (fr) Procédé de traitement de troubles mentaux, comportementaux et cognitifs
EP3906043A4 (fr) Procédés et compositions pour le traitement de la maladie de fabry
EP3999084A4 (fr) Methodes et produits pour le traitement de troubles gastro-intestinaux
EP3681477A4 (fr) Méthode et composition améliorée pour le traitement d&#39;états pathologiques, de maladies ou de troubles sensibles aux triterpènes
EP3858353A4 (fr) Composition pharmaceutique pour prévenir et traiter la nitm et utilisation pharmaceutique associée
EP3492096A4 (fr) Composition pharmaceutique pour le traitement de maladies oculaires, contenant une protéine cas9 et un arn guide
EP3818085A4 (fr) Compositions et leurs utilisations pour traiter une maladie ou un état pathologique
EP3570670A4 (fr) Compositions et procédés de traitement de maladies et de troubles du stockage lysosomial
EP3979985A4 (fr) Compositions et méthodes pour traiter des troubles du système nerveux central
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3922264A4 (fr) Composition pharmaceutique permettant la prévention, l&#39;amélioration ou le traitement de maladies de la peau
EP3943107A4 (fr) Composition pour prévenir ou traiter une maladie du cerveau et du système nerveux
EP3755319A4 (fr) Composés et compositions pour le traitement de troubles musculaires
EP4034109A4 (fr) Méthode et composition pour le traitement d&#39;une maladie
EP3558281A4 (fr) Traitement de troubles mentaux, du mouvement et du comportement
EP3600324A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP4043012A4 (fr) Médicament pour le traitement de maladies artérielles et son utilisation
EP3946433A4 (fr) Compositions, dispositifs et méthodes de traitement de la maladie de fabry
EP4010075A4 (fr) Méthodes pour le traitement de maladies et de troubles liés à l&#39;apoc3

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: H01M0010040000

Ipc: A61K0031270000

A4 Supplementary search report drawn up and despatched

Effective date: 20221214

RIC1 Information provided on ipc code assigned before grant

Ipc: H01M 4/00 20060101ALI20221208BHEP

Ipc: H01M 10/26 20060101ALI20221208BHEP

Ipc: H01M 10/04 20060101ALI20221208BHEP

Ipc: A61P 25/28 20060101ALI20221208BHEP

Ipc: A61K 31/55 20060101ALI20221208BHEP

Ipc: A61K 31/445 20060101ALI20221208BHEP

Ipc: A61K 31/27 20060101AFI20221208BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240206